Edition:
United Kingdom

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

43.70USD
12 Dec 2017
Change (% chg)

$-1.35 (-3.00%)
Prev Close
$45.05
Open
$45.25
Day's High
$45.35
Day's Low
$43.45
Volume
229,116
Avg. Vol
237,654
52-wk High
$60.15
52-wk Low
$19.30

Latest Key Developments (Source: Significant Developments)

Fibrogen Inc reports Q3 loss per share $0.50
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Fibrogen Inc ::Fibrogen reports third quarter 2017 financial results.Q3 loss per share $0.50.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.nda filing for roxadustat for anemia in​ ckd with u.s. Food and drug administration targeted for 2018.qtrly ‍total revenue $27.3 million versus $30.1 million.  Full Article

Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Fibrogen Inc :Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD).Fibrogen - ‍under terms of Fibrogen's agreement with Astrazeneca, NDA submission triggers a $15 million milestone payment, payable to co by Astrazeneca​.  Full Article

Fibrogen reports Q2 EPS of $0.39
Monday, 8 Aug 2016 

Fibrogen Inc : Fibrogen reports financial results for the second quarter of 2016 . Q2 earnings per share $0.39 . Q2 earnings per share view $0.36 -- Thomson Reuters I/B/E/S . Qtrly total revenue $89.3 million versus $120.6 million .Q2 revenue view $78.5 million -- Thomson Reuters I/B/E/S.  Full Article

Fibrogen announces receipt of $62 million license payment from Astrazeneca
Friday, 8 Jul 2016 

Fibrogen Inc : Fibrogen announces receipt of $62 million license payment from Astrazeneca .Astrazeneca,Co collaborating on development,commercialization of drug for treatment of Anemia in patients with CKD in U.S., China, other markets.  Full Article

Fibrogen Q1 loss per share $0.45
Monday, 9 May 2016 

Fibrogen Inc : Fibrogen reports financial results for the first quarter of 2016 . Q1 loss per share $0.45 .Q1 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S.  Full Article

FibroGen Inc publishes phase 2 anemia data for roxadustat
Tuesday, 16 Feb 2016 

FibroGen Inc:FibroGen publishes encouraging phase 2 anemia data demonstrating roxadustat's ability to maintain hemoglobin levels in patients with chronic kidney disease.Says roxadustat was well tolerated in the study population.Treatment-emergent adverse events were reported in 63 percent of all patients in the safety population.  Full Article

BRIEF-Fibrogen Inc reports Q3 loss per share $0.50

* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S